secwatch.observer — SEC 8-K summary
======================================

Issuer:     NORTHWEST BIOTHERAPEUTICS INC (NWBO)
CIK:        0001072379
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001104659-24-037901
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Northwest Biotherapeutics appoints Pat Sarma as Class II director effective March 18, 2024
--------------------------------------------------------------------------------

- Pat Sarma appointed as Class II director and to Audit, Compensation, and Conflicts Committees.
- No arrangements or related-party transactions in connection with his appointment.
- Compensation will be on same basis as other non-employee directors.
- Appointment date: March 18, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1072379/000110465924037901/0001104659-24-037901-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1072379/000110465924037901/tm249577d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-037901

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer